Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial

INTRODUCTION: Early tumor shrinkage (ETS), depth of response (DpR), and time to DpR represent exploratory endpoints that may serve as early efficacy parameters and predictors of long-term outcome in metastatic colorectal cancer (mCRC). We analyzed these endpoints in mCRC patients treated with first-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurreck, Annika, Heinemann, Volker, Fischer von Weikersthal, Ludwig, Decker, Thomas, Kaiser, Florian, Uhlig, Jens, Schenk, Michael, Freiberg-Richter, Jens, Peuser, Bettina, Denzlinger, Claudio, Graeven, Ullrich, Heinrich, Kathrin, Held, Swantje, Stahler, Arndt, Alig, Annabel Helga Sophie, Jelas, Ivan, von Einem, Jobst C., Stintzing, Sebastian, Giessen-Jung, Clemens, Modest, Dominik P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895369/
https://www.ncbi.nlm.nih.gov/pubmed/35251955
http://dx.doi.org/10.3389/fonc.2022.751453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895369/
https://www.ncbi.nlm.nih.gov/pubmed/35251955
http://dx.doi.org/10.3389/fonc.2022.751453

Ejemplares similares